#ESMO22: Amgen spotlights confirmatory win for KRAS G12C player Lumakras in lung cancer — but there's plenty more data to come
PARIS — Amgen came to Paris with a two-step plan to reveal confirmatory CodeBreak 200 trial data for its KRAS G12C drug Lumakras in non-small cell lung cancer. After tipping its cards ahead of the conference to stake a top-line claim — sans data — on hitting the primary endpoint for median progression-free survival over docetaxel at 12 months, we’re getting the initial snapshot that details just how the comparison stacks up.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.